Lantheus Holdings(US:LNTH)2021-05-06 14:37Financial Performance - The company reported revenues of $92.5 million in Q1 2021, a 2% increase year-over-year[39] - Free cash flow was $7.3 million in Q1 2021, compared to $6.7 million in Q1 2020[39] - Adjusted net income was $3.3 million, or $0.05 per share, compared to $14.3 million, or $0.36 per share in Q1 2020[39] - The company had $68.9 million in unrestricted cash and cash equivalents as of March 31, 2021[39] Product Performance - DEFINITY sales increased, driven by sequentially higher volumes, but with regional differences[44] - TechneLite volumes are returning to pre-COVID-19 levels[44] - Other precision diagnostics revenue decreased by 46.5% due to the sale of Puerto Rico operations[44] - Strategic partnerships and other revenue increased by 1,230.1%, driven by newly acquired assets[44] Strategic Initiatives - The company is preparing for the potential FDA approval and commercial launch of PyL[57] - The company acquired exclusive worldwide rights to NTI-1309, an innovative PET oncology imaging agent[34] - The company voluntarily repaid in full the entire outstanding principal on the RELISTOR Royalty-Backed Loan[51] Financial Guidance - The company issued revenue guidance for Q2 2021 of $93 million - $97 million[55] - The company issued adjusted fully diluted EPS guidance for Q2 2021 of $0.03 - $0.06[55] - The company updated FY 2021 revenue guidance to $390 million - $400 million[55] - The company updated FY 2021 adjusted fully diluted EPS guidance to $0.36 - $0.41[55]